Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

MGI Pharma commences phase II liver cancer trial with irofulven

Oct. 3, 2000

NIH grants anti-Notch-1 monoclonal antibody technology to Viragen

Oct. 3, 2000

Migration-inhibitory peptides identified and investigated at Kyowa Hakko

Oct. 2, 2000

Chugai examines novel enzyme inhibitors as potential anticancer agents

Oct. 2, 2000

Beacon describes preparation and activity of improved butyric acid esters

Oct. 2, 2000

New approach to oncolytic, skin disorders based on specific inhibition of 4-hydroxylase

Oct. 2, 2000

Sigma-Tau selects new camptothecin derivative for preclinical development

Oct. 2, 2000

Northwest's prostate cancer vaccine shows favorable progress in clinical trial

Oct. 2, 2000

3-D researchers patent alphav integrin inhibitors with broad indications

Sep. 29, 2000

Two-antigen combination melanoma vaccine enters phase I/II at MGH

Sep. 29, 2000

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...